摘要
目的针对儿童精神分裂症患儿长程治疗中联合用药合理性及影响因素进行探讨。方法回顾性选取儿童精神分裂症患儿155例,根据患儿长程治疗中是否进行联合用药分为单一用药组(82例)和联合用药组(73例)。统计两组临床基线资料,对其进行单因素分析,以儿童精神分裂症患儿联合用药作为因变量,将单因素分析结果中差异有统计学意义的指标作为自变量进行多因素Logistic回归分析,筛选出儿童精神分裂症患儿联合用药的影响因素;分析患儿联合用药合理性;比较两组患儿不良反应发生情况。结果单因素分析结果显示:联合用药组患儿始发年龄(7.15±0.67)岁小于单一用药组的(12.58±1.66)岁,住院天数(50.61±12.31)d长于单一用药组的(29.45±6.11)d,住院次数(6.05±1.17)次多于单一用药组的(3.14±0.97)次,存在显著差异(P<0.05)。以儿童精神分裂症患儿联合用药作为因变量,将单因素分析结果中差异有统计学意义的指标作为自变量,进行多因素Logistic回归分析,结果显示:始发年龄、住院天数、住院次数均是儿童精神分裂症患儿联合用药的影响因素(P<0.05)。在73例联合用药患儿中,合理联用患儿有64例(87.67%),不合理联用患儿有9例(12.33%);二联用药患儿为63例(86.30%),三联及以上联合用药患儿为10例(13.70%)。联合用药组总不良反应发生率49.32%(36/73)高于单一用药组的26.83%(22/82),存在显著差异(P<0.05)。结论始发年龄、住院天数、住院次数均是儿童精神分裂症联合用药的影响因素,虽然合理联用药物的占比较高,但仍存在不良反应发生风险,因此,临床治疗时应根据具体情况选择合理的用药方案,以降低不良反应发生率。
Objective To explore the influencing factors and rationality of combined medication in long-term treatment of children with schizophrenia.Methods A total of 155 children with schizophrenia were retrospectively selected,and divided into the single medication group(82 cases)and the combined medication group(73 cases)according to whether combined medication was involved in long-term treatment.The clinical baseline data of the two groups were statistically analyzed and univariate analysis was performed.Using the combined medication for children with schizophrenia as the dependent variable and the indicators with statistically significant differences in the results of univariate analysis as independent variables,a multivariate Logistic regression analysis was conducted to screen out the influencing factors of combined medication for children with schizophrenia;the rationality of combined medication was analyzed;the occurrence of adverse reactions was compared.Results The results of univariate analysis showed that the age of onset of the children in the combined medication group[(7.15±0.67)years of age]was lower than that in the single medication group[(12.58±1.66)years of age],the hospitalization days[(50.61±12.31)d]was longer than that in the single medication group[(29.45±6.11)d],and the hospitalization times[(6.05±1.17)times]was more than that in the single-medication group[(3.14±0.97)times].There was a significant difference(P<0.05).Using the combined medication for children with schizophrenia as the dependent variable and the indicators with statistically significant differences in the results of univariate analysis as independent variables,a multivariate Logistic regression analysis was conducted,the results showed that age of onset,hospitalization days,and hospitalization times were all influencing factors of combined medication for children with schizophrenia(P<0.05).Among the 73 cases of combined medication,64 cases(87.67%)were rational,9 cases(12.33%)were irrational.There were 63 cases(86.30%)of patients with two drugs and 10 cases(13.70%)of patients with three or more drugs.The incidence of total adverse reactions in the combined medication group was 49.32% (36/73), which was higher than 26.83% (22/82) in the single medication group, and there was a significant difference (P<0.05). Conclusion The age of onset, days of hospitalization and number of hospitalizations are all influencing factors of combined medication for children with schizophrenia. Although the proportion of rational drug combination is relatively high, there is still a risk of adverse reactions. Therefore, rational drug use schemes should be selected according to specific conditions in clinical treatment to reduce the incidence of adverse reactions.
作者
郭宇
GUO Yu(Department of Pharmacy,Inner Mongolia Mental Health Center,Hohhot 010010,China)
出处
《中国实用医药》
2024年第17期121-123,共3页
China Practical Medicine
关键词
儿童
精神分裂症
联合用药
影响因素
合理性
Children
Schizophrenia
Combined medication
Influencing factors
Rationality
